drugset / Trial / NCT07122193

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT07122193

Phase 3 Active not recruiting 300 enrolled Merz North America, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: Main Period (MP) and Open label Extension Period (OLEX).

Timeline

Start
2025-08-27
Primary completion
2026-10
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic Intramuscular

Indications

No indication recorded.